$1.25 million awarded to progress University of Queensland-developed prostate cancer drug

Development of a new drug based on research at The University of Queensland, targeting advanced and therapy-resistant prostate cancer, has been awarded $1.25 million from the US-based Critical Path Institute’s Translational Therapeutics Accelerator. According to a statement from UQ on Tuesday, the drug named QED-203 has its origins in research by Professor Greg Monteith from…

“Expansibility, flexibility, and distributability”: Experts identify why some companies thrive in crises

Researchers have boiled down the qualities that have helped companies thrive during crises, such as online platforms Uber and Alibaba during the Covid-19 pandemic, or Birdseye Frozen Foods during the Second World War.  Crises are times “when normal societal functions often deteriorate,” explained Associate Professor Frederik von Briel in a statement from University of Queensland on…

Manufacturing news briefs — stories you might have missed

Memphasys claims defining milestone for Felix Reproductive technology company Memphasys has announced the successful data from a “pivotal clinical trial” for the Felix System, “confirming its best-in-class performance in sperm selection for Assisted Reproductive Technology (ART).” Conducted in partnership through Monash IVF, Memphasys said on Monday that the trial results show Felix as “non-inferior to…

UQ biotech innovation partnership forges a second startup

A new startup aimed at discovering and developing anti-inflammatory disease medicines has been formed by The University of Queensland’s commercialisation arm UniQuest and global biotech company Molecule to Medicine (MTM), according to a statement released on Tuesday. Curlew Bio will leverage expertise from the Queensland Emory and Drug Discovery Initiative (QEDDI) and research developed by…